Roche has more at risk than Genentech

Swiss drugmaker Roche is seeking to force a deal for the 44% of Genentech it doesn’t already own, by putting a slightly lower bid of $86 a share directly to shareholders. Roche is betting that economic turmoil in the past six months left Genentech shareholders anxious to raise cash from their stakes.